← All trials
NCT02725528
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 8, 2017
- Primary completion
- Dec 17, 2021
- Completion date
- Dec 17, 2021
- First posted
- Apr 1, 2016
- Last posted
- Jul 18, 2023
- Enrollment
- 22
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- McMaster UniversityLead sponsor
- McMaster UniversityOverall official - principal investigator
- McMaster UniversityReponsible party - principal investigator
- The Physicians' Services Incorporated FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.